National Drug Schedules

including but not limited to abiraterone acetate

for human use

when recommended for administration by intravenous injection

up to and including 650 mg per unit, in package sizes containing no more than 50 units

in strengths of greater than 650 mg per unit or in package sizes of more than 50 units

for human use

including but not limited to adefovir dipivoxil

when sold or recommended for administration by intravenous injection

for human use including but not limited to: Betamethasone valerate, betamethasone sodium, betamethasone phosphate, betamethasone dipropionate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone sodium, dexamethasone phosphate, dexamethasone acetate, difluprednate, fludrocortisone acetate, flunisolide, fluticasone propionate, fluticasone furoate, hydrocortisone acetate, hydrocortisone aceponate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone succinate, methylprednisolone sodium, mometasone furoate, prednisolone acetate, prednisolone sodium, prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide except: (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other nonprescription medicinal ingredient that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (c) clobetasone butyrate when sold in a concentration of 0.05% in cream preparations for topical use on the skin; or (d) triamcinolone acetonide in a nasal spray that delivers 55 microgram (mcg)/spray for those 12 years of age and older; or, (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older; or (f) fluticasone propionate for the treatment of allergic rhinitis in a nasal spray that delivers 50 microgram/spray for those 18 years of age and older.

including but not limited to citric acid, glycolic acid, lactic acid, malic acid, mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium, when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations of greater than 30% and/or with a pH lower than 3.0, except when sold to be applied to warts, corns or calluses

including but not limited to alfaxalone, alphaxolone

including but not limited to tenecteplase

PDL, including but not limited to amikacin sulfate

for human use

(5-phenyl-4, 5-dihydro-1, 3-oxazol-2-amine), its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analogues, including 4-Methylaminorex (4-methyl-5-phenyl-4, 5-dihydro-1, 3-oxazol-2-amine) and 4,4'-Dimethylaminorex (4-methyl-5-(4-methylphenyl)-4, 5-dihydro-1, 3-oxazol-2-amine)

including but not limited to mesalazine

including but not limited to dronedarone

including but not limited to fosamprenavir

for human use

for human use, except preparations for topical use

except otic preparations

for otic use

for human use

including but not limited to fosaprepitant

including but not limited to asenapine maleate

when sold for administration by injection

including but not limited to atropine sulphate, in ophthalmic or parenteral preparations

including but not limited to ivermectin, selamectin, doramectin

including but not limited to azatadine

for topical use

including but not limited to benazepril hydrochloride

including but not limited to bendamustine hydrochloride

in concentrations greater than 5% or when sold in combination with another medicinal ingredient

including but not limited to benzatropine

for human use, when sold or recommended for the treatment of homocystinuria

for veterinary use

(except when sold in concentrations of 5mg or less per oral dosage unit or 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl)

including but not limited to Bosutinib methanoate

including but not limited to onabotulinumtoxin A, incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B

including but not limited to candesartan cilexetil

its preparations and derivatives, as listed in the schedules to the Controlled Drugs and Substances Act and the Narcotic Control Regulations

including but not limited to: cefdinir, cefepime, cefonicide, cefoperazone, cefpodoxime proxetil, cefprozil, ceftazidime, ceftibuten, ceftolozane, cefuroxime, lorcarbef.

see hydroxyzine or its salts or derivatives

in concentrations of 10mg equivalent to 8.5mg or less of cetirizine base per dosage unit) in products marketed for adult use (age 12 and over)

except in preparations for external use

for human use when used as a topical oral preparation

for human use

for human use

for human use

when sold in combination with magnesium salicylate

for veterinary use

except when sold in concentrations of 200 milligrams or less per oral dosage unit and indicated for the treatment of heartburn

when sold in concentrations of 100 mg or less per dosage unit and indicated for the treatment of heartburn

for human use

for veterinary use, including but not limited to closantel sodium

for human use, except in preparations for topical or vaginal use

for human use in preparations for intra-vaginal use

including but not limited to colesevelam hydrochloride

including but not limited to colistimethate

when recommend for the debridement of severe burns and skin ulcers

except sodium cromoglicate (cromoglycate) in solutions for ophthalmic or nasal use in concentrations of 2% or less [*see sodium cromoglicate (cromoglycate)]

for human use

in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada

including but not limited to ciclosporin

including but not limited to cyproterone acetate

including but not limited to dabigatran etexilate

when used in an injectable form

except when used in an injectable form

for veterinary use

in products marketed for adult use - 12 years and older

including but not limited to desvenlafaxine succinate

for veterinary use

when sold as a single medicinal ingredient for topical use on the skin for not more than 7 days - in concentrations greater than 1.16% and less than or equal to 2.32% - in package sizes containing no more than 2.6g of diclofenac diethylamine

when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days

including (but not limited to): diclofenac diethylamine, diclofenac sodium, diclofenac potassium, except when sold as a single medicinal ingredient for topical use on the skin in a concentration equivalent to 2% or less of diclofenac for not more than 7 days

ovine

for veterinary use

for human use

except in preparations for topical use on the skin

for topical use on the skin

for veterinary use

including but not limited to cabazitaxel

when sold for administration by injection

including but not limited to doxycycline hyclate, doxycycline monohydrate

except those sold for nausea and vomiting of pregnancy

when sold or recommended for use in the nausea or vomiting of pregnancy

including but not limited to eltrombopag olamine

including but not limited to emamectin benzoate

including but not limited to enalapril maleate

in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion.

for human use

including but not limited to eribulin mesylate

including but not limited to tulathromycin

including but not limited to erythropoietin, darbepoetin alpha, epoetin alfa

including but not limited to esomeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg in package sizes of no more than 280 mg of esomeprazole

for veterinary use

including but not limited to dexfenfluramine

including but not limited to fingolimod hydrochloride

in solid oral dosage forms containing more than 1 mg of fluoride ion

in oral preparations containing 1 mg or less of fluoride ion per dosage unit

including but not limited to capecitabine, tegafur

including but not limited to: follitropin alpha, follitropin beta, follitropin delta

except glycopyrronium bromide, including but not limited to glycopyrrolate, when used orally or for inhalation

including but not limited to glycopyrrolate, when used orally or for inhalation

including but not limited to aurothioglucose, auranofin and sodium aurothiomalate, when sold for administration by injection

for veterinary use

when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in children under 2 years of age

when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing more than 30 g

when sold in a concentration that provides 1% or less hydrocortisone in preparations for topical use on the skin in adults and children 2 years of age and over in package sizes containing no more than 30 g

when recommended as an antidote for cyanide poisoning

including but not limited to acenocoumarol when sold or recommended as anticoagulants

including but not limited to cetirizine and hydroxyzine hydrochloride except cetirizine or its salts when sold in concentration greater than 8.5 milligrams cetirizine per unit dose

when recommended for parenteral use

except when sold in an oral dosage form that provides 400 mg or less per dosage unit or in a modified-release oral dosage form that provides 600 mg or less per dosage unit

when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit

including but not limited to Icatibant acetate

for veterinary use, including but not limited to ferumoxytol, for all routes of administration but parenteral

for human use, including but not limited to ferumoxytol, iron isomaltoside 1000, for parenteral use only

for use in the treatment of head lice

when recommended for parenteral use as a tissue sclerosing agent

in preparations in concentrations of more than 10% except when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations greater than 30% and/or with a pH lower than 3.0 for a use other than to be applied to warts, corns or calluses

when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher

for otic use

for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]

For veterinary use

except in oral dosage form that provides 1 milligram (mg) or less per daily dose

when sold in concentrations greater than 25 mg per dosage unit

when sold in concentrations of 25 mg or less per dosage unit

including but not limited to doripenem